Tiziana Life Sciences (NASDAQ: TLSA) is a clinical-stage biotechnology company developing novel therapeutics in the areas of oncology, immunology and virology. Headquartered in London with research and development operations in King of Prussia, Pennsylvania, Tiziana leverages a dual small-molecule and biologics platform to address immune-mediated diseases and viral infections. Since its founding in 1998, the company has focused on translating laboratory discoveries into clinical candidates, advancing programs through early- and mid-stage human trials.
The company’s lead therapeutic candidates include a humanized anti-CD3 monoclonal antibody originally developed to prevent organ transplant rejection and now repurposed to moderate hyperinflammatory responses in viral infections, a class of selective Bruton’s tyrosine kinase (BTK) inhibitors targeting B-cell malignancies and myelofibrosis, and a next-generation anti-CD24 antibody designed to inhibit tumor growth in solid cancers. Tiziana’s anti-CD3 program is in Phase II development for acute respiratory distress syndrome (ARDS) associated with severe viral illnesses. Its BTK inhibitors have demonstrated compelling preclinical activity against chronic lymphocytic leukemia and related hematologic disorders, and the anti-CD24 asset has shown early signs of immune checkpoint modulation in solid tumor models.
Historically, Tiziana has combined in-house discovery capabilities with strategic collaborations, partnering with contract research organizations and academic centers in Europe and North America. The company maintains active clinical trial sites across the United States and the United Kingdom, and it continues to expand its global footprint through regulatory filings and investigator-led studies. Tiziana’s cross-functional leadership team is led by a chief executive officer with more than two decades of experience in drug development, supported by experts in immunology, oncology, translational research and regulatory affairs.
Through its integrated approach, Tiziana Life Sciences aims to deliver differentiated therapies for patients suffering from life-threatening diseases. The company’s pipeline reflects a commitment to addressing unmet medical needs by harnessing insights into immune regulation and viral pathogenesis. As a publicly traded entity on the NASDAQ, Tiziana seeks to advance its novel therapeutic portfolio through continued clinical progress, strategic partnerships and disciplined capital management.
AI Generated. May Contain Errors.
